Grant of Share Options under Share Option Scheme
Updated : 09:46
Grant of Share Options under Share Option Scheme
London: Tuesday, December 15, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that on December 14, 2020, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting on April 24, 2015 (the "Share Option Scheme"). The scheme limit of the Share Option Scheme was refreshed on April 27, 2020.
Chi-Med granted share options under its Share Option Scheme to employees to subscribe for a total of 1,535,580 Ordinary Shares represented by 307,116 American Depositary Shares ("ADSs") (each equating to five Ordinary Shares) subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:
Date of grant | : | December 14, 2020
|
Exercise price of share options granted | : | US$29 per ADS
|
Number of share options granted | : | 1,535,580 represented by 307,116 ADSs (five share options shall entitle the holder thereof to subscribe for one ADS)
|
Closing market price of ADSs on the date of grant
| : | US$29 per ADS
|
Validity period of the share options | : | From December 14, 2020 to December 13, 2030 |
Among the share options granted, a total of 58,570 share options represented by 11,714 ADSs were granted to Mr Christian Hogg and Dr Weiguo Su (Executive Directors of the Company), being persons discharging managerial responsibility under the EU Market Abuse Regulation as follows:-
Grantee | Number of share options granted | |
Mr Christian Hogg (Executive Director and Chief Executive Officer) | 39,610 Ordinary Shares represented by 7,922 ADSs
| |
Dr Weiguo Su (Executive Vice President and Chief Scientific Officer) | 18,960 Ordinary Shares represented by 3,792 ADSs
|
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
(a) Mr Christian Hogg
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) |
Name |
Mr Christian Hogg
| ||||||
2 | Reason for the notification | |||||||
a) |
Position/status |
Executive Director and Chief Executive Officer
| ||||||
b) |
Initial notification/Amendment
|
Initial notification
| ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) |
Name
|
Hutchison China MediTech Limited | ||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) |
Description of the financial instrument, type of instrument
Identification code
|
Option over American Depositary Share (each equating to five Ordinary Shares of US$0.10)
Option over American Depositary Share with ADS ISIN: US44842L1035
| ||||||
b) |
Nature of the transaction
|
Grant of options in respect of 39,610 Ordinary Shares represented by 7,922 ADSs under the Share Option Scheme.
The share options granted are exercisable subject to a vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the effective date of grant.
| ||||||
c) |
Price(s) and volume(s) |
| ||||||
d) |
Aggregated information
|
N/A | ||||||
e) |
Date of the transaction |
2020-12-14
| ||||||
f) |
Place of the transaction |
Outside a trading venue
|
(b) Dr Weiguo Su
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) |
Name |
Dr Weiguo Su
| ||||||
2 | Reason for the notification | |||||||
a) |
Position/status |
Executive Director and Chief Scientific Officer
| ||||||
b) |
Initial notification/Amendment
|
Initial notification
| ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) |
Name
|
Hutchison China MediTech Limited | ||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) |
Description of the financial instrument, type of instrument
Identification code
|
Option over American Depositary Share (each equating to five Ordinary Shares of US$0.10)
Option over American Depositary Share with ADS ISIN: US44842L1035
| ||||||
b) |
Nature of the transaction
|
Grant of options in respect of 18,960 Ordinary Shares represented by 3,792 ADSs under the Share Option Scheme.
The share options granted are exercisable subject to a vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the effective date of grant.
| ||||||
c) |
Price(s) and volume(s) |
| ||||||
d) |
Aggregated information
|
N/A | ||||||
e) |
Date of the transaction |
2020-12-14
| ||||||
f) |
Place of the transaction |
Outside a trading venue
|
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President | +852 2121 8200 |
Annie Cheng, Vice President | +1 (973) 567 3786 |
Media Enquiries |
|
Americas - Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) |
Europe - Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
Asia - Joseph Chi Lo / Zhou Yi, Brunswick | +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com |
Nominated Advisor | |
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.